Neovacs will partner with 3P
Biopharmaceuticals to manufacture interferon alpha (IFNa) following its purchase of technology from
AMEGABIOTECH.
“This partnership is in line with the recent license agreement
signed with AMEGABIOTECH,” Neovacs CEO Miguel Sieler said. “The completion of
these two steps allows us to secure the complete production chain for the
manufacture of IFNa, one of the primary raw materials of our most advanced
product, IFNa Kinoid. In addition, the agreement complements the partnership
signed earlier this year with Stellar Biotechnologies, the supplier of the
other main component of our vaccine IFNa Kinoid, Keyhole Limpet Hemocyanin."
Within the framework of this partnership, Stellar Biotechnologies holds 30 percent of
Neostell, the production subsidiary of Neovacs.
Neovacs’ licensing agreement with AMEGABIOTECH will result in
the direct transfer of the technology used to manufacture IFNa directly to 3P
Biopharmaceuticals. The transfer of the technology directly to 3P will
guarantee the manufacturing of the IFNa cytokine.
3P Biopharmaceuticals is the
only Spanish manufacturer of biological products in the health care field.
Alerts Sign-up